Bavituximab: Phase I/II data

Data from 9 patients with advanced HCC in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 0.3, 1 and 3 mg/kg doses of bavituximab plus twice-daily 400 mg sorafenib for 28 days led to no serious adverse events or dose-limiting toxicities (DLTs). The most common adverse events were hand-foot syndrome, fatigue and anorexia. The trial is now enrolling patients in the Phase II portion of the trial to receive weekly 3 mg/kg bavituximab plus twice-daily 400 mg sorafenib. Data were presented at the American Association for Cancer Research meeting in Chicago. The trial was sponsored by the University of Texas Southwestern Medical Center. ...